Proposed Data Collections Submitted for Public Comment and Recommendations, 73332-73333 [E8-28552]
Download as PDF
<![CDATA[
73332
Federal Register / Vol. 73, No. 232 / Tuesday, December 2, 2008 / Notices
Name
............................
............................
............................
............................
............................
62
63
64
65
............................
............................
............................
............................
66
67
68
98
70
71
72
73
74
75
76
77
78
79
80
jlentini on PROD1PC65 with NOTICES
57
58
59
60
61
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
............................
4,4′-METHYLENEBIS(2-CHLOROANILINE) ............................................................................................
PENTACHLOROBENZENE .....................................................................................................................
1,3-BUTADIENE .......................................................................................................................................
1,1-DICHLOROETHANE ..........................................................................................................................
1,2,3,4,6,7,8,9-OCTACHLORODIBENZOFURAN ....................................................................................
HEPTACHLORODIBENZOFURAN ..........................................................................................................
2,3,4,7,8-PENTACHLORODIBENZOFURAN ...........................................................................................
HEXACHLORODIBENZOFURAN ............................................................................................................
PENTACHLORODIBENZOFURAN ..........................................................................................................
2,3,7,8-TETRACHLORODIBENZOFURAN ..............................................................................................
DIBENZOFURANS, CHLORINATED .......................................................................................................
1,2,3,4,6,7,8-HEPTACHLORODIBENZOFURAN .....................................................................................
1,2,3,7,8,9-HEXACHLORODIBENZOFURAN ..........................................................................................
TETRACHLORODIBENZOFURAN ..........................................................................................................
1,2,3,6,7,8-HEXACHLORODIBENZOFURAN ..........................................................................................
1,2,3,4,7,8-HEXACHLORODIBENZOFURAN ..........................................................................................
2,3,4,6,7,8-HEXACHLORODIBENZOFURAN ..........................................................................................
1,2,3,7,8-PENTACHLORODIBENZOFURAN ...........................................................................................
1,2,3,4,7,8,9-HEPTACHLORODIBENZOFURAN .....................................................................................
1,1,2-TRICHLOROETHANE .....................................................................................................................
HEXACHLOROCYCLOPENTADIENE .....................................................................................................
1,2-DIPHENYLHYDRAZINE .....................................................................................................................
1,2-DICHLOROETHENE, TRANS- ..........................................................................................................
1,2-DICHLOROETHYLENE .....................................................................................................................
1,2-DICHLOROETHENE, CIS- ................................................................................................................
CARBON DISULFIDE ..............................................................................................................................
PALLADIUM .............................................................................................................................................
CHLOROETHANE ....................................................................................................................................
ACETONE ................................................................................................................................................
DIBENZOFURAN .....................................................................................................................................
2,4-DIMETHYLPHENOL ..........................................................................................................................
CARBON MONOXIDE .............................................................................................................................
CHLOROMETHANE .................................................................................................................................
BUTYL BENZYL PHTHALATE ................................................................................................................
VANADIUM ...............................................................................................................................................
N-NITROSODIMETHYLAMINE ................................................................................................................
1,2,4-TRICHLOROBENZENE ..................................................................................................................
N-NITROSODIPHENYLAMINE ................................................................................................................
2-BUTANONE ..........................................................................................................................................
FLUORINE ...............................................................................................................................................
HYDROGEN FLUORIDE .........................................................................................................................
FLUORIDE ION ........................................................................................................................................
Submission of Nominations for the
Evaluation Set 23 Proposed Substances:
Today’s notice also invites voluntary
public nominations for substances not
listed in this notice. Nominations are
most useful if they include the full
name, title, affiliation, e-mail address
and telephone number of the nominator.
ATSDR will evaluate all data and
information associated with nominated
substances and will determine the final
list of substances that will be chosen for
toxicological profile development.
Substances will be chosen according to
ATSDR’s specific guidelines for
selection, found in the Selection Criteria
announced in the Federal Register on
May 7th, 1993 (87 FR 27288).
Please submit nominations by one of
the following methods:
• E-mail jxt1@cdc.gov.
• Fax 770.488.4178.
• Mail CDR Jessilynn Taylor, 1600
Clifton Rd, NE., MS F32, Atlanta, GA
30333.
VerDate Aug<31>2005
CAS
20:52 Dec 01, 2008
Jkt 217001
Please ensure that your comments are
submitted within the specified
nomination period. Nominations
received after the closing date will be
marked as late and may be considered
only if time permits.
Dated: November 26, 2008.
Ken Rose,
Director, Office of Policy, Planning, and
Evaluation National Center for Environmental
Health/Agency for Toxic Substances and
Disease Registry.
[FR Doc. E8–28551 Filed 12–1–08; 8:45 am]
BILLING CODE 4163–70–P
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
000101–14–4
000608–93–5
000106–99–0
000075–34–3
039001–02–0
038998–75–3
057117–31–4
055684–94–1
030402–15–4
051207–31–9
042934–53–2
067562–39–4
072918–21–9
030402–14–3
057117–44–9
070648–26–9
060851–34–5
057117–41–6
055673–89–7
000079–00–5
000077–47–4
000122–66–7
000156–60–5
000540–59–0
000156–59–2
000075–15–0
007440–05–3
000075–00–3
000067–64–1
000132–64–9
000105–67–9
000630–08–0
000074–87–3
000085–68–7
007440–62–2
000062–75–9
000120–82–1
000086–30–6
000078–93–3
007782–41–4
007664–39–3
016984–48–8
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–09–09AG]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 or send
comments to Maryam Daneshvar, Acting
CDC Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
E:\FR\FM\02DEN1.SGM
02DEN1
73333
Federal Register / Vol. 73, No. 232 / Tuesday, December 2, 2008 / Notices
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
An Assessment of the Acceptability of
Pre-exposure Prophylaxis (PrEP) Among
Inner City Persons At Risk for HIV/
AIDS—New—National Center for HIV,
Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
New HIV infections, both in the U.S.
and globally are continuing at an
unacceptably rapid rate and are rising in
some sites and sub-populations. Despite
the many behavioral interventions
available, it is necessary to develop
additional highly effective prevention
modalities, including biomedical ones if
we are to significantly reduce the
number of new HIV infections. Preexposure prophylaxis (PrEP) is currently
under intense investigation as a
potential biomedical intervention for
the prevention of HIV acquisition.
Clinical trials are underway in
populations at high risk of acquiring
HIV in Asia (injection drug users),
Africa (heterosexuals and discordant
couples), Latin America (men who have
sex with men [MSM]), and among MSM
in the United States. Based on the high
efficacy shown with antiretroviral
prophylaxis for the prevention of HIV
transmission to infants during
pregnancy, birth, and breastfeeding; and
on the protection against vaginal or
rectal exposure prophylaxis studies
with non-human primates, it is likely
that one of more of these human trials
will show efficacy.
The purpose of the proposed study is
to conduct a preliminary assessment of
attitudes about, preferences for
programmatic introduction of, and
anticipated changes in risk behaviors
resulting from PrEP among young adults
in neighborhoods and social networks
where risk behaviors are likely to lead
to HIV exposure. An early
Number of
responses per
respondent
Number of
respondents
Types of data collection
understanding of the perspective of
intended users is critical to planning for
possible use of PrEP.
Investigators at Georgia State
University, in collaboration with
NCHHSTP, will conduct 20 focus
groups in the first year, and 50
ethnographic individual interviews in
the second year, with a largely AfricanAmerican population of young adults,
ages 18–24. Study participants will be
recruited from the 10 zipcodes in
Atlanta, GA with the highest HIV/STD
prevalence. The focus group and
interview guides will cover six major
areas: (1) Healthcare access and use; (2)
risk perception in their social network;
(3) knowledge and understanding of
HIV transmission; (4) positive and
negative attitudes toward a clinic-based
HIV prevention program that involves
daily doses of an antiretroviral with
periodic HIV testing and risk
counseling; (5) preferences for the
design of such a program (e.g., where
would it best be located); (6) whether
they anticipate any changes in their risk
behavior if engaged in such a program.
In the second year, rapid HIV testing
will be offered to individual interview
participants, with referrals for
prevention or treatment services as
indicated by test results.
There is no cost to respondents other
than their time.
Average
burden per response
(in hours)
Total burden
(in hours)
Focus Group Participants ................................................................................
Ethnographic Interviews ..................................................................................
160
50
1
1
2
2
320
100
Total ..........................................................................................................
........................
........................
........................
420
Dated: November 21, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–28552 Filed 12–1–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
jlentini on PROD1PC65 with NOTICES
[30Day–09–08AO]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
VerDate Aug<31>2005
20:52 Dec 01, 2008
Jkt 217001
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
omb@cdc.gov.
Proposed Project
Children’s Peer Relations and the Risk
for Injury at School—New—National
Center for Injury Prevention and Control
(NCIPC), Coordinating Center for
Environmental Health and Injury
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
Prevention (CCEHIP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Injuries are responsible for more
deaths than all other causes combined
for people under 19. In 2003, the
Centers for Disease Control and
Prevention (CDC) estimated that,
annually, one in four children sustained
an injury severe enough to warrant
medical care, school absence, or bed
rest. It was determined that an
investigation of modifiable risk factors
for childhood injuries is necessary to
improve the health of children.
The Division of Unintentional Injury
Prevention at the CDC will investigate
the relationship between a child’s social
behaviors and experiences at school and
their school injuries. Peer nominated
and teacher rated social behaviors will
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 73, Number 232 (Tuesday, December 2, 2008)]
[Notices]
[Pages 73332-73333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-28552]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-09-09AG]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960 or
send comments to Maryam Daneshvar, Acting CDC Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA
[[Page 73333]]
30333 or send an e-mail to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
An Assessment of the Acceptability of Pre-exposure Prophylaxis
(PrEP) Among Inner City Persons At Risk for HIV/AIDS--New--National
Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
New HIV infections, both in the U.S. and globally are continuing at
an unacceptably rapid rate and are rising in some sites and sub-
populations. Despite the many behavioral interventions available, it is
necessary to develop additional highly effective prevention modalities,
including biomedical ones if we are to significantly reduce the number
of new HIV infections. Pre-exposure prophylaxis (PrEP) is currently
under intense investigation as a potential biomedical intervention for
the prevention of HIV acquisition. Clinical trials are underway in
populations at high risk of acquiring HIV in Asia (injection drug
users), Africa (heterosexuals and discordant couples), Latin America
(men who have sex with men [MSM]), and among MSM in the United States.
Based on the high efficacy shown with antiretroviral prophylaxis for
the prevention of HIV transmission to infants during pregnancy, birth,
and breastfeeding; and on the protection against vaginal or rectal
exposure prophylaxis studies with non-human primates, it is likely that
one of more of these human trials will show efficacy.
The purpose of the proposed study is to conduct a preliminary
assessment of attitudes about, preferences for programmatic
introduction of, and anticipated changes in risk behaviors resulting
from PrEP among young adults in neighborhoods and social networks where
risk behaviors are likely to lead to HIV exposure. An early
understanding of the perspective of intended users is critical to
planning for possible use of PrEP.
Investigators at Georgia State University, in collaboration with
NCHHSTP, will conduct 20 focus groups in the first year, and 50
ethnographic individual interviews in the second year, with a largely
African-American population of young adults, ages 18-24. Study
participants will be recruited from the 10 zipcodes in Atlanta, GA with
the highest HIV/STD prevalence. The focus group and interview guides
will cover six major areas: (1) Healthcare access and use; (2) risk
perception in their social network; (3) knowledge and understanding of
HIV transmission; (4) positive and negative attitudes toward a clinic-
based HIV prevention program that involves daily doses of an
antiretroviral with periodic HIV testing and risk counseling; (5)
preferences for the design of such a program (e.g., where would it best
be located); (6) whether they anticipate any changes in their risk
behavior if engaged in such a program. In the second year, rapid HIV
testing will be offered to individual interview participants, with
referrals for prevention or treatment services as indicated by test
results.
There is no cost to respondents other than their time.
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Types of data collection Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Focus Group Participants........................ 160 1 2 320
Ethnographic Interviews......................... 50 1 2 100
---------------------------------------------------------------
Total....................................... .............. .............. .............. 420
----------------------------------------------------------------------------------------------------------------
Dated: November 21, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E8-28552 Filed 12-1-08; 8:45 am]
BILLING CODE 4163-18-P
